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WHAT THIS PAPER ADDS
 This study is a signiﬁcant milestone in the development of drug-eluting polyester vascular prosthesis using a polymer of cyclo-
dextrins. It addresses experimentally the safety and the efﬁcacy of these prostheses before this innovative concept could be applied
in clinical medicine. For that reason, this study is unique. The inﬂuence of this concept could be tremendous in the near future since
one might be able to load speciﬁc bioactive molecules, especially antibiotics, onto a graft or stent graft according to therapeutic
goals.a r t i c l e i n f o
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Objectives: Polyester vascular prostheses (PVPs) coated with a polymer of hydroxypropyl-b-cyclodextrin
(HPbCD) have been designed to provide an in situ reservoir for the sustained delivery of one or more
bioactive molecules. The goal of this study was to assess the efﬁcacy, the safety and the healing prop-
erties of these prostheses.
Methods: Collagen-sealed PVPs were coated with the HPbCD-based-polymer (PVP-CD) using the padedry
ecure textile ﬁnishing method and loaded with one or two antibiotics. Appropriate control and PVP-CD
samples were tested in several in vitro and animal model conditions. The study end points included
haemolysis, platelet aggregation, antibacterial efﬁcacy, polymer biodegradation, acute toxicity and
chronic tolerance.
Results: PVP-CD proved to be compatible with human blood, since it did not induce haemolysis nor
inﬂuenced ADP-mediated platelet aggregation. Sustained antimicrobial efﬁcacy was achieved up to 7
days against susceptible bacteria when PVP-CDs were loaded with the appropriate drugs. Analysis of
harvested PVP-CD from the animal model revealed that the HPbCD-based coating was still present at 1
month but had completely disappeared 6 months after implantation. All grafts were patent, well
encapsulated without healing abnormalities. Clinical data, blood-sample analysis and histological
examination did not evidence any signs of acute or chronic, local or systemic toxicity in the animal
models.
Conclusion: PVP-CD was proved safe and demonstrated excellent biocompatibility, healing and degra-
dation properties. Effective antimicrobial activity was achieved with PVP-CD in conditions consistent
with a sustained-release mechanism.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.ulaire, Hôpital Cardiologique,
320 445 005; fax: þ33 320
aulon).
ciety for Vascular Surgery. PublisheThe sealing of polyester (Dacron) vascular prostheses (PVPs) is
usually achieved with a collagen or a gelatine biodegradable matrix
that degrades within 1e3 months of implantation.1e3 During
surgery, the sealing agent prevents blood permeation through thed by Elsevier Ltd. All rights reserved.
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strategies designed to confer to those sealants speciﬁc therapeutic
properties and to improve prosthetic graft outcomes. Disappoint-
ingly, this investment is yet to yield any great advance. Severe
complications arise following prosthesis implantation despite
constant reﬁnements in surgical techniques and biomaterials.
Infection is probably one of the most disastrous complications
and is likely to occur in up to 6% of patients undergoing vascular
surgery.4e6 Given the small but potentially catastrophic risk of
infection of implanted vascular grafts, their activation with anti-
microbial agents targeted to speciﬁc pathogens has become an
appealing concept to improve their resistance to infection. Simi-
larly, development of such infection-resistant biomaterials would
be of great value in instances of in situ reconstruction after removal
of conﬁrmed vascular infected grafts.7,8
Both native cyclodextrins (CDs) and their synthetic derivatives
such as hydroxypropyl-b-cyclodextrin (HPbCD) are shaped as cage
molecules with a hydrophobic internal cavity and a hydrophilic
external surface.9 Due to hydrophobic interactions with their
internal part, they can encapsulate numerous active molecules,
including antiseptics and antibiotics, and then release the preloaded
molecules unmodiﬁed over a prolonged period of time. Formation
of such complexes has been reported to result in delayed and sus-
tained drug delivery.10,11 The coating of PVP with a HPbCD-based-
polymer (PVP-CD) is aimed to provide an in situ reservoir for the
sustained delivery of one or more antimicrobials over several days.
Reported evidences of renal toxicity of native CDs when
administered parenterally had however limited their use to non-
parenteral administration routes.12 The newer synthetic deriva-
tive HPbCD has demonstrated a signiﬁcantly better safety proﬁle
and provides a novel opportunity for extending the use of CDs to
various administration routes.13 HPbCD has been extensively
studied with regard to parenteral safety in a number of animal
species and in humans, with no adverse effects documented to date
on kidney function.14 Despite this highly reported inocuity of
HPbCD monomers, the safe use of PVP-CD remains to be ascer-
tained. The goal of this study was to assess the efﬁcacy, the safety
and the healing properties of these prostheses.
Material and Methods
Vascular prostheses
TwotypesofmanufacturedPVPwereprovidedbyPerouseMedical
(Ivry-Le-Temple, France): collagen-sealed weaved (Polythese) and
collagen-sealed knitted (Polymaille) PVP. Both types were used
either unmodiﬁed as commercially available or after HPbCD coating.
The coating process was carried out using the padedryecure textile
ﬁnishingmethod,aspreviouslydescribed.15During theprocess, cross-
linking of HPbCD moieties by citric acid (CTR) occurred though
esteriﬁcation reactions and resulted in a cross-linked CTR-HPbCD
polymer that physically adhered to the PVP ﬁbres. Both PVP-CD and
uncoated-PVP were sterilised before use by gamma irradiation and
stored in appropriate conditions (15e25 C, safe from light and
humidity).
Platelet aggregation assay
Platelet-rich plasma (PRP) was prepared by centrifuging whole
human blood from healthy volunteers at 1150 rpm for 15 min. Prior
informed consent was obtained from every volunteer. The super-
natant PRP was drawn off and the remaining blood centrifuged
further at 4000 rpm for 15 min at room temperature to yield the
platelet-poor plasma (PPP). PVP-CD (test article) and high-density
polyethylene (control-article) were extracted with 0.9% sodiumchloride (NaCl) for 24 h at 70 C under agitated conditions (80 rpm)
at a ratio of 3 cm2 ml1. Test and control-article extracts were
incubated with PRP at 37 C for 5 min. Aggregation tests were
conducted in the presence and absence of adenosine diphosphate
(ADP, 5 mM). The aggregation proﬁles were monitored as a change
in optical density for 5 min using an aggregometer calibrated with
aggregation of PPP scored as 100 and PRP scored as zero.
Haemolysis test
Haemolysis tests were conducted on leachables extracted from
PVP-CD (test article) in accordance with the International Organi-
sation for Standardisation (ISO) 10993-4 standards. To prepare
immersion extracts, samples of the test article were incubated in
Falcon tubes with Dulbecco’s phosphate-buffered saline (DPBS) at
37 C for 72 h under agitated conditions (80 rpm). The relation
between the material surface and the volume of solution was
3 cm2 ml1 as in the previous experiment. Falcon tubes without
samples ﬁlled with DPBS only and incubated in the same conditions
served as negative control. Blood samples were collected in
ethylene diamine tetraacetic acid (EDTA) tubes from healthy
donors and diluted in DPBS to obtain blood substrate containing
10 g l1 total haemoglobin. Prior informed consent was obtained
from every donor. One millilitre portions of the resulting dilution
were transferred to tubes containing the test-article extracts (n¼ 3)
or the control vehicle (DBPS only; n¼ 3). Tubes were maintained in
a stationary position during 3 h at 37 C, with the exception of
gentle inversions twice every 30 min. The suspensions were then
centrifuged at 3250 rpm for 15 min and the plasma haemoglobin
(free haemoglobin) was measured on the collected supernatants
using a spectrophotometer at 540 nm. The Haemolytic Index (HI)
calculated as follows determined haemolytic activity of the sample:
HI (%) ¼ free haemoglobin (g l1)  8  100/total haemoglobin
(g l1) in the diluted blood substrate. Data were expressed as the
mean percentage  SD of three separate experiments. HI will
satisfy the standard of an implantable medical device when it is
below 5%.16
Antibiotic loading
PVP-CD specimens were immersed for 20 min at room
temperature under agitated conditions (200 rpm) in an antibiotic
aqueous solution just prior to the experiments. This resulted in
loading the grafts with a signiﬁcant amount of antibiotics as
previously demonstrated.5 Antibiotic solutions used during this
study included rifampin (RFP; Rifadine 600 mg, Sanoﬁ-Aventis) at
60 g l1, vancomycin hydrochloride (VCY; Vancomycine 500 mg,
Mylan) at 50 g l1, ciproﬂoxacine (CFX; 200 mg, Panpharma) at
2 g l1 or a combination of rifampin 60 g l1 plus ciproﬂoxacine
2 g l1 (RFP þ CFX).
Antibacterial activity overtime
Bacterial strains used to assess this activity were methicillin-
resistant Staphylococcus aureus (MRSA) 07001 and Escherichia coli
L70A4. Samples (6-mm diameter cut discs) of antibiotic-loaded
PVP-CD were dipped individually in human blood plasma
(Etablissements Français du Sang, Lille, France) for 7 days at 37 C
under agitated conditions (80 rpm). The plasma milieu was
renewed every day during this time period. Thus, the antibiotics
diffusing into the plasma medium would be sooner or later des-
orbed from the grafts as previously shown.5 Bacteria were cultured
from cryopreservative beads (80 C) onto inclined Müller-Hinton
agar ﬂasks at 37 C for 24 h in aerobic conditions. A bacterial
suspension was prepared in cysteinated one-quarter strength
Figure 1. Flow-chart outlining the canine study design (PVP ¼ polyester vascular
prosthesis; PVP-CD ¼ polyester vascular prosthesis coated with cyclodextrin; PVP-CD-
ATB ¼ polyester vascular prosthesis coated with cyclodextrin and loaded with
antibiotics).
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Hinton agar plates were then inoculated with this suspension
(0.1 ml/plate). Fifteen minutes thereafter, samples in triplicates of
each tested material were removed from human plasma, rinsed
with DPBS and placed ﬁrmly in appropriate inoculated plates. This
was carried out at t0 and every 24-h period over the 7-day stay in
human plasma. Each plate was subsequently incubated at 37 C for
24 h aerobically. Zones of inhibition around the discs were
measured as the mean diameter of the clear area surrounding
a disc, in which bacteria were not able to proliferate. The results
were plotted over time. Efﬁcacy at any time point was noted if an
inhibition radius of at least 10 mm was present.17,18 This was con-
ducted for MRSA and E. coli in two separate experiments.
Acute toxicity test
Twenty naïve female Albino Swiss mice (Mus musculus)
weighting 17e22 g, from Charles River Laboratories (L’Abresle,
France), were used in this study. The animals were fed a regular
rodent diet and allowed to acclimate for at least 5 days before
beginning the experimental procedures. In accordance with ISO
10993-11, extracts of the prosthesis coated with the CTR-HPbCD
polymer were prepared by immersion at 37 C for 72 h in either
0.9%-NaCl solution or sesame oil under a ratio of 3 cm2 ml1. The
mice (ﬁve per group) were either injected intravenously with saline
extracts (50 ml kg1) or intra-peritoneally with sesame oil extracts
(50 ml kg1). The extraction vehicles without test article were
similarly prepared and injected to serve as negative controls. Based
on guidelines provided in the United States Pharmacopoeia,
animals were weighted and observed for adverse reactions
(Table 1) immediately and at 4, 24, 48 and 72 h after injection.19
Healing properties and chronic toxicity
Twenty-four female mongrel dogs (Canis familiaris) weighting
23e30 kg, from Marshall BioResources (Lyon, France), were fed
a regular diet and allowed to acclimate for at least 12 days before
beginning the experiment. Two groups of dogs (Fig. 1) were bilat-
erally implanted in carotid arteries using 6-mm diameter PVP to
construct an in vivo functional implantation model. Group-1
animals (n ¼ 12) received randomly the PVP-CD on one side and
the uncoated-PVP on the other. Group-2 animals (n ¼ 12) received
randomly the PVP-CD on one side and an antibiotic-loaded PVP-CD
on the other (RFP, n¼ 2; CFX, n¼ 2; VCY, n¼ 2). This was carried out
according to the European requirements (EEC directive 86/609) for
the care and use of experimental animals. Moreover, the institu-
tional ethic committee approved the study protocols.
Under general anaesthesia (induction, thiopental 10e15mg kg1
intramuscularly; maintenance, O2eN2Oeisoﬂourane 0.5e4%),
exposure of right and left carotid arteries was performed. SystemicTable 1
Criteria to assess acute systemic toxicity after intravenous or intraperitoneal
injection in a mouse model.
Grade Response Description
0 Normal No adverse physical symptoms
1 Slight Slight but noticeable symptoms:
Hypokinesia, dyspnoea, abdominal irritation
2 Moderate Symptoms deﬁnitely evident: Hypokinesia, dyspnoea,
ptosis, diarrhoea, abdominal irritation,
weight drops to between 15 and 17 g
3 Marked Severe symptoms: Prostration, cyanosis, tremors,
convulsion, abdominal irritation, diarrhoea, ptosis,
dyspnoea, extreme weight loss (weight < 15 g)
4 Death Mouse dies after injectionanticoagulationwas achieved by a single injection of unfractionated
sodium heparin (50 IU kg1). Each dog received cephalexin
(30 mg kg1 day1) immediately and for 3 postprocedural days. The
calibre of carotid artery external diameter was assessed and the
artery clamped upstream and downstream before a 3e4 cm arterial
segment was resected. The prosthesis was implanted into the gap
with twoend-to-endanastomoses constructedwith a polypropylene
suture. Closure was performed according to standard surgical prac-
tice and the incisionwas injectedwith butorphanol for postoperative
analgesia. Animals were returned to individual cages receiving
aspirin per os (75 mg day1) for 1 month and thoroughly examined
daily. Blood samples were analysed (creatinine, alanine amino-
transferase (AlAT), aspartate aminotransferase (ASAT) and bilirubin)
to assess renal and hepatic functions at the implantation date, at 1
month and at 6months. Animalswere sacriﬁced by a lethal injection
of barbiturate at 1 month (half of each group) or at 6 months.Macroscopic examination
Local tolerance, graft patency and incorporation were assessed
following animal euthanasia and harvesting of PVP. Gross exam-
ination of the implantation site, the implanted prosthesis and of
all major organs (heart, lungs, liver, kidney and brain) was carried
out followed by sampling any representative abnormal tissue.
A 10%-buffered formalin solution was used to ﬁx those speci-
mens. Parameters assessed during gross examination are dis-
played in Table 2.Figure 2. Platelet aggregation assay in the absence or presence of adenosine diphos-
phate (ADP) for PVP-CD (polyester vascular prosthesis coated with HPbCD), high-
density polyethylene and 0.9% NaCl solution (data are expressed as mean  SD). P-
values are as determined for each condition by KruskaleWallis test.
Figure 4. Macroscopic aspects of harvested polyester vascular prosthesis (PVP) coated or not
not with antibiotics after 6-month implantation in a canine model of carotid bypass. Top:
showing a slight grade of mural thrombus and the mismatch calibre between the graft and
Figure 3. A: Antibacterial activity overtime (N ¼ 3) of uncoated-polyester vascular
prosthesis (PVP, control), of polyester vascular prosthesis coated with hydroxyl-propyl-
b-cyclodextrin loaded with rifampin (PVP-CD þ RFP), with ciproﬂoxacin (PVP-
CD þ CFX) or with rifampin and ciproﬂoxacin (PVP-CD þ RFP/CFX) against methicilin-
resistant-Staphylococcus-aureus (MRSA). P-values (PVP vs PVP-CD þ RFP, p < 0.0001;
PVP vs PVP þ CFX, p ¼ 0.06; PVP vs PVP-CD þ RFP/CFX, p < 0.0001; PVP-CD þ CFX vs
PVP-CD þ RFP, p < 0.0001; PVP-CD þ CFX vs PVP-CD þ RFP/CFX, p < 0.0001; PVP-
CD þ RFP vs PVP-CD þ RFP/CFX, p ¼ 0.59) are as determined by ANOVA followed by
Fischer PLSD test. B: Antibacterial activity overtime (N ¼ 3) of uncoated-polyester
vascular prosthesis (PVP, control), of polyester vascular prosthesis coated with
hydroxyl-propyl-b-cyclodextrin loaded with rifampin (PVP-CD þ RFP), with cipro-
ﬂoxacin (PVP-CD þ CFX) or with rifampin and ciproﬂoxacin (PVP-CD þ RFP/CFX)
against Escherichia coli (E. coli). P-Values (PVP vs PVP-CD þ RFP, p ¼ 0.34; PVP vs
PVP þ CFX, p < 0.0001; PVP vs PVP-CD þ RFP/CFX, p < 0.0001; PVP-CD þ CFX vs PVP-
CD þ RFP, p < 0.0001; PVP-CD þ CFX vs PVP-CD þ RFP/CFX, p ¼ 0.37; PVP-CD þ RFP vs
PVP-CD þ RFP/CFX, p < 0.0001) are as determined by ANOVA followed by Fischer
PLSD test.
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After ﬁxation, biopsy samples from PVP and perigraft tissue
were dehydrated in alcohol solutions of increasing concentration,
cleared in xylene, embedded in parafﬁn and sectioned at 4e7 mm
using a microtome. Two sections per specimen were stained with
Masson’s Trichome. Semiquantitative evaluation concerning the
degree of inﬂammation was graded20 from 0 to 4: absent ‘0’, slight
‘1’, moderate ‘2’, marked ‘3’ and severe ‘4’ for each assessed
parameter (Table 2).
CTR-HPbCD-polymer biodegradation
Two-cm-length sections were recovered from each harvested
PVP-CD. The amount of CTR-HPbCD-polymer remaining on these
sections was assessed by the semiquantitative toluidine blue oxide
(TBO) staining method21 using a spectrophotometer at 634 nm. The
TBO cationic dye would interact both with the COOH groups
present on the CTR cross-links and with the HPbCD cavities such
that amount of sorbed TBO and that of CTR-HPbCD-polymer were
strictly proportional. Uncoated PVP and non-implanted PVP-CD
specimens were used as controls.
Statistical analysis
Statistical calculations were carried out using StatView 6.0
software (SAS Institute, Cary, NC, USA). When comparing two
groups, continuous variables were analysed with the Man-
neWhitney U-test for unpaired data or with the Wilcoxon signed-
rank test for paired data. For multiple comparisons or for repeated
measures, the KruskaleWallis test or the analysis of variance
(ANOVA) was used to compare the data as appropriate. Statistical
signiﬁcance was assumed at p  0.05.
Results
Platelet aggregation assay
Fig. 2 displays the platelet aggregation rates for PVP-CD, control
material and 0.9%-NaCl used as vehicle. There were no statistically
signiﬁcant differences between the tested samples either inwith hydroxyl-propyl-b-cyclodextrin (PVP-CD; uncoated-PVP) loaded (PVP-CD-ATB) or
external surface showing further encapsulation and healing; bottom: luminal surface
the native carotid artery.
Table 3
Local tolerance of different vascular prosthesesa as assessed by gross examinationb
at 1 and 6 months post-implantation in a canine model.
Grade at 1-month Grade at 6-month
PVP PVP-CD PVP-CD
+ATB
PVP PVP-CD PVP-CD
+ATB
Erythema 0 0 0 0 0 0
Oedema 0 0e1 1e2 0 0 0
Seroma 0e2 0e2 1e2 0 0e2 0
Haemorrhage 0e1 0e1 1e2 0e2 1e2 1e2
Neovascularisation 1e2 1e2 1e2 1e2 0 0e1
Fibrosis development 2e3 2e3 2e3 1e2 1e2 1
Necrosis 0 0 0 0 0 0
Neointima formation 0 0 0 1e2 0e1 1
Tissular hyperplasia 0 0 0 0 0 0
Prosthetic dilatation 0e2 0e2 1 0e1 0e1 0
a PVP: uncoated-polyester vascular prosthesis; PVP-CD: HPbCD coated-polyester
vascular prosthesis; PVP-CD+ATB: HPbCD coated-polyester vascular prosthesis
loaded with antibiotics.
b Gross-examination scale extends from 0 (absent), 1 (slight), 2 (moderate), 3
(marked) to 4 (severe or total) grade. Data are expressed as Mean  SD.
Table 2
Assessed parameters and grade-scale for gross and histological examinations of harvested polyester vascular prosthesis or perigraft tissue samples in a functional
canine-implantation model.
Assessed parameters Semi-quantitative scale
Macroscopic evaluation Microscopic evaluation Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Thrombogenicity Thrombus Absent Slight Moderate Marked Severe or total
Seroma Fibrin
Polymorphonuclears
Oedema Macrophages
Lymphocytes
Erythema Plasma cells
Giant cells
Necrosis Necrosis
Fibrous tissue development Fibroblasts
Peri-implant ﬁbrosis
Tissular hyperplasia Tissular integration
Calciﬁcation
Graft dilatation Implant degradation
Neovascularisation Neovascularisation
Neointima Endothelial-like cells
Myointimal hyperplasia
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neither induced platelet aggregation nor did it inﬂuence ADP-
mediated platelet aggregation.
Haemolysis test
The mean HI for DPBS (negative control) and for the PVP-CD
extracts was 0.63%  0.12% and 0.94%  0.4%, respectively
(p ¼ 0.51). PVP-CD likewise the negative control did not induce
haemolysis when in contact with human blood (HI far less than 5%)
and can be considered as highly haemocompatible.
Antibacterial activity overtime
In this experiment, the antimicrobial activity of different tested
PVP supports over a 7-day period desorption in human plasmawas
assessed (Fig. 3(A) and (B)). The control material (uncoated-PVP)
did not inhibit any bacterial proliferation. Declining but sustained
antimicrobial efﬁcacy (up to 7 days) was evidenced against MRSA
with PVP-CD loadedwith RFP (Fig. 3(A)), against E. coliwith PVP-CD
loaded with CFX (Fig. 3(B)) and against either bacterium with PVP-
CD loaded with the RFP þ CFX association. Neither synergistic nor
antagonistic effects were depicted though (Fig. 3(A) and (B)), since
one would expect with the antibiotic association greater or lesser
activity, respectively. Of note, PVP-CD loaded with CFX only failed
against MRSA while PVP-CD with RFP only failed against E. coli,
both after the ﬁrst-day desorption in human plasma.
Acute toxicity test
No mortalities or clinical evidence of acute systemic toxicity
after PVP-CD extracts’ injectionwere documented inmice that have
all displayed a normal response throughout the study. Body weight
gains of treated mice were similar to their respective controls (data
not shown).
Healing properties and chronic toxicity
All PVP implantation procedures were successfully carried out.
There were no perioperative deaths or signs of clinical abnormali-
ties. Mean external carotid artery diameter was: 3.8 0.3, 3.9 0.2
and 4.0  0.4 mm in PVP-CD, PVP-CD loaded with antibiotics and
uncoated-PVP implantation sites (p ¼ NS), respectively. All grafts
were patent at the end of the corresponding follow-up period andwell encapsulated (Fig. 4). There were at 6 months some intra-
luminal thrombi allocated to the calibre mismatch between the
6-mm PVP and a 50% smaller carotid artery (Fig. 4). Findings
from microscopic analysis of these thrombi were not consistent
with infection and did not mandate any further microbiological
examination.
Pooled data from macroscopic evaluation at termination are
reported in Table 3 and showed that PVP-CD and uncoated-PVP
were well tolerated locally and systemically at 1 month and at 6
months in all implanted animals. There were no grossly visible
lesions in any major organ at animal sacriﬁce but one mongrel dog,
implanted with uncoated PVP on one side and with PVP-CD loaded
with RFP on the other side, was found dead at 4 months. Post-
mortem histological analysis performed on this dog showed
marked cerebral focal haemorrhagic necrosis, hepatic multifocal
cholestasis, spleen red pulp hyperplasia and at both implantation
sites a periprosthetic marked graded neutrophilic inﬁltration. All of
these ﬁndings were consistent with intercurrent sepsis and prob-
ably related to the chronic multiresistant staphylococcal infection
evidenced on bacteriological analyses. Of note, the involved
Staphylococcal aureus strain was found only vulnerable to enro-
ﬂoxacine, a CFX-like quinolone.
Data from blood-samples analysis throughout the study are
displayed in Fig. 5(A)e(E). There was no impairment of renal or
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signiﬁcant rise in serum creatinine level was observed (compared
with preoperative and 1-month values). The kidneys (Fig. 6) did not
display any macroscopic abnormalities that would mandate further
histological examination.
Prosthetic and implantation sites’ histological examination did
not reveal tissue alterations indicative of sub-acute (1 month) orFigure 5. (AeE): Blood samples analysis results before implantation, at 1-month and at 6-m
b-cyclodextrin in carotid position of mongrel-dogs. Data are expressed as the median with th
before implantation paired with those at 1-month or at 6-months. A: creatinine; B: ALAT; C
expected normal clinical range despite statistical signiﬁcance difference between time-perichronic (6 month) toxicity for PVP-CD loaded or not with antibi-
otics as compared with uncoated-PVP (Tables 4 and 5). A slight to
moderate grade of inﬂammatory inﬁltrate and ﬁbrous tissue
(Fig. 7(A)) was noted at 1month around all three groups of PVP. At 6
months, myointimal hyperplasia (Fig. 7(B)) was graded slight for
uncoated PVP and slight tomoderate for PVP-CD loaded or not with
antibiotics (Table 5).onths after implantation of polyester vascular prosthesis coated with hydroxyl-propyl-
e inter-quartile range. *P-values as determined byWilcoxon signed-rank test for values
: ASAT; D: total bilirubin and E: anorganic phosphates. All values are always within the
ods sometimes.
Figure 6. Macroscopic aspects of the kidneys (canine model) 6-months after PVP-CD implantation in carotid position.
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The rate of sorbed TBO onto harvested PVP-CD was not changed
at 1 month but at 6 months returned closely to the level observed
in the uncoated PVP (Fig. 8). This suggested that CTR-HPbCD
coating was still present after 1 month and had almost completely
disappeared before the 6 month post-implantation.
Discussion
Vascular implantable devices are ideal drug-delivery systems
because they allow local delivery of active agents to the injuredTable 4
Semi-quantitative data of histological analysisa at 1-month post-implantation of
vascular prosthesisb in a functional canine model of carotid bypass.
PVP PVP-CD PVP-CD+ATB
Fibrin 1e2 1e2 1e2
Patency 4 4 4
Thrombus 0 0 0
Necrosis 0 0 0
Polymorphonuclears 0e1 0e1 0e2
Lymphocytes 0e1 0e1 0e1
Plasma cells 0 0 0
Macrophages 2 2 2
Giant cells 1 1 1
Fibroblasts 1 1 1e2
Peri-Implant ﬁbrosis 1 1 1e2
Neovascularisation 1 1 1
Calciﬁcation 0 0 0
Implant degradation 0 0 0
Endothelial-like cells 1 1 1
Neointimal thickness 1 1 1
Myointimal hyperplasia 1e2 1e2 1
Tissular integration 1 1 1
a Histological examination scale extends from 0 (absent), 1 (slight), 2 (moderate),
3 (marked) to 4 (severe or total) grade. Data are expressed as Mean  SD.
b PVP: uncoated-polyester vascular prosthesis; PVP-CD: HPbCD coated-polyester
vascular prosthesis; PVP-CD+ATB: HPbCD coated-polyester vascular prosthesis
loaded with antibiotics.area, avoiding the need to deliver high doses systemically.
Despite active and intensive research in cardiovascular biomate-
rials,22 only coronary drug-eluting stents have reached routine
clinical practice. Their current common usage highlights the
potential beneﬁts of pharmacologically functional implantable
medical devices. The polyethylene terephthalate (PET) or e-pol-
ytetraﬂuoroethylene (e-PTFE) fabric of vascular grafts and stent
grafts could offer a broader surface to use and a greater appli-
cability than traditional bare stents. This experimental study
represents a step further towards an effective drug-eluting PVP as
a 7-day antimicrobial activity was achieved against susceptible
bacteria.Table 5
Semi-quantitative data of histological analysisa at 6-month post-implantation of
vascular prosthesisb in a functional canine model of carotid bypass.
PVP PVP-CD PVP-CD+ATB
Fibrin 1e2 0e2 0e1
Patency 2e4 2e4 2e4
Thrombus 0e2 0e2 0e2
Necrosis 0 0 0
Polymorphonuclears 0e1 0e1 0e1
Lymphocytes 0e1 0 0e1
Plasma cells 0 0 0e1
Macrophages 1e2 1e2 1e2
Giant cells 0e1 1e2 1
Fibroblasts 2 2 1e2
Peri-Implant ﬁbrosis 2 2 2
Neovascularisation 1 1 1
Calciﬁcation 0 0 0
Implant degradation 0 0 0
Endothelial-like cells 2 1e2 2e3
Neointimal thickness 2 1e2 1e2
Myointimal hyperplasia 1 1e2 1e2
Tissular integration 2e3 2e3 2e3
a Histological examination scale extends from 0 (absent), 1 (slight), 2 (moderate),
3 (marked) to 4 (severe or total) grade. Data are expressed as Mean  SD.
b PVP: uncoated-polyester vascular prosthesis; PVP-CD: HPbCD coated-polyester
vascular prosthesis; PVP-CD+ATB: HPbCD coated-polyester vascular prosthesis
loaded with antibiotics.
Figure 7. A: Histological analysis of implantation sites of polyester vascular prosthesis coated (PVP-CD) or not (uncoated-PVP) with hydroxyl-propyl-b-cyclodextrin loaded (PVP-
CD-ATB) or not with antibiotics after 1-month implantation in a canine model of carotid bypass. Top: anastomotic site overview; middle: peri-implant ﬁbrous tissue; and bottom:
inﬂammatory inﬁltrate around the prosthesis. Masson’s trichrome staining, light microscopy: *ﬁbroblast proliferation; **prosthetic material; ***dense inﬂammatory inﬁltrate
(Numerous neutrophils, very few monocytes). B: Histological analysis of implantation sites of polyester vascular prosthesis coated (PVP-CD) or not (uncoated-PVP) with hydroxyl-
propyl-b-cyclodextrin loaded (PVP-CD-ATB) or not with antibiotics after 6-month implantation in a canine model of carotid bypass. Masson’s Trichome staining, light microscopy
showing: Top, implantation site overview; middle, the myointimal hyperplasia with sparse endothelial-like cells; and bottom, the tissular integration; (*ﬁbroblast; **prosthetic
material; bEndothelial-like cells; bb Smooth muscle cells). In polarized light microscopy some attempts of foreign material phagocytises were evidenced (slide not shown).
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Figure 8. Biodegradation in vivo of the hydroxyl-propyl-b-cyclodextrin polymer after
implantation of coated-polyester vascular prosthesis in the carotid artery of dogs. The
amount of CTR-HPbCD polymer was measured as the toluidine blue oxide (TBO)-sor-
bed rate before implantation of the graft, at 1-month and at 6-month post-
implantation. Uncoated polyester vascular prosthesis served as control. *P-value as
determined for each time period by ManneWhitney test.
E. Jean-Baptiste et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 188e197196Our data demonstrated that implantation of PVP-CD is
biocompatible and safe. There was no evidence of local or
systemic toxicity. Within 6 months, PVP-CD was like uncoated
PVP, well incorporated into surrounding tissues and without
healing abnormalities. A mild inﬂammatory reaction did occur,
but according to Murphy et al.,23 neutrophils and monocytes
normally migrate to sites of PVP implantation and are important
in graft incorporation.
Only a very slight difference was noted at 6 months regarding
myointimal hyperplasia between PVP-CD and uncoated-PVP
samples, but within clinically acceptable range in both cases.
Although mural thrombus was noted along the grafts, this was due
to calibre mismatch and did not differ between PVP-CD and
uncoated PVP. In addition, PVP-CD performed satisfactorily at
platelet aggregation assay. Suspicion of infection-related throm-
bosis was similarly ruled out based upon histological data, although
no further microbiological investigations were undertaken.
Safety24 is a primary concern when considering new excipients
intended for use in pharmaceutical formulations.12 The literature
provides many references demonstrating the use of CDs to enhance
oral bioavailability of active compounds.25 In this study, blood
sample analysis and histological tests did not show any impairment
of renal or hepatic function after PVP-CD implantation. This is
consistent with the ﬁndings of the most recent investigations into
CD polymers and CDs conjugated to other delivery vehicles, namely
nanoparticles and liposomes.26
Native CDs are known to induce shape changes and membrane
invagination on human erythrocytes, and eventually induce hae-
molysis at higher concentrations.27 In this study, PVP-CD did not
induce haemolysis in contact with human blood. The haemolytic
activity of native CDs correlates with their inclusion ability towards
membrane lipids rather than their intrinsic solubility or surface
activity.27 When the character of their lipophilic cavity is modiﬁed
by chemical derivatisation (e.g., HPbCD), the effects on cell
membranes may be tremendously modiﬁed.12 Moreover, CDs lose
their ability to interact with cell membranes when guest molecules
occupy their cavities.27 This supports further why PVP-CD loaded
with a bioactive molecule should be unlikely to induce haemolysis
in clinical applications.
Most grafts become contaminated by local ﬂora during the
initial placement procedure or within the weeks following
implantation from adjacent or remote infection sites. The clinical
onset may be instantaneous (<1 month), early (<4 months) or late
(>4 months) depending whether the causative pathogen is highly
virulent, virulent or relatively indolent. Both prolonged (>24 h)
systemic prophylactic antibiotic treatment and local prophylacticrifampicin bonding to PVP did not prevent vascular graft infection
after arterial reconstructions in a Cochrane systematic review.28
Broad-spectrum systemic antibiotic prophylaxis may not be
always adapted or may not reach the prosthetic implantation site at
adequate concentration. Rifampicin is used locally without always
taking into account the identity or antimicrobial susceptibilities of
the involving organisms. Infections can also be polymicrobial. Most
commonly implicated causative organisms produce bioﬁlms with
a barrier effect sustaining bacterial colonisation and protecting
encased organisms from host defences and systemic antimicrobial
therapy.29 In this study, sustained antimicrobial efﬁcacy was ach-
ieved in vitro up to 7 days against susceptible bacteria when PVP-
CDs were loaded with the appropriate drugs. With this strategy,
it might be possible to customise the local therapy to maintain for
several days high and effective doses of one or more selected
antimicrobial agents according to the ecology of the vascular graft
infection. Further works are ongoing to assess this strategy with
other antimicrobial agents and to possibly adapt it to anti-
thrombotics, anticoagulants and mitotic spindle inhibitors. All
these molecules could address common issues encountered after
vascular graft and stent-graft implantation, namely patency,
thombogenicity, myointimal hyperplasia, etc.
Potential limitations of this study may be related to the lack of
an animal model to assess in vivo the sustained antimicrobial efﬁ-
cacy and to the lack of analyses using scanning electronmicroscopy.
This would allow polymer integrity to be assessed after PVP-CD
implantation, bioﬁlm formation to be evaluated after bacterial
contamination and incubation and interactions between bacteria
and the HPbCD-based polymer to be determined.
Conclusion
PVP-CD has been proved safe and demonstrated excellent
biocompatibility, healing and degradation properties in vitro and in
animalmodels. Effective antimicrobial activity was achieved in vitro
with PVP-CD in conditions suggestive of a sustained-release
mechanism. Further studies are needed to assess this drug-
delivering strategy with other antimicrobial agents according to
bacteria susceptibility or with other bioactive compounds
depending on the therapeutic goals. Dedicated in vivo animal
models are required to conﬁrm the antimicrobial efﬁcacy and to
assess the clinical relevance of this drug-delivering strategy before
speciﬁc trials of safety and efﬁcacy could be undertaken in humans.
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